[Fluorouracil and high-dose folinic acid in the treatment of advanced colorectal carcinoma]. 1990

M Natali, and M D'Aprile, and G Tonini, and M Leggio, and P Vici, and S Carpano, and F Angelini, and A Carassai, and M Lopez
Centro Oncologico Giorgio Porfiri, Latina.

Forty-five consecutive patients with advanced colorectal cancer were treated with 5-fluorouracil and high dose folinic acid. Among 43 evaluable patients there were 7 objective responses for an overall response rate of 16%. Toxicity was generally mild and rapidly reversible. Compared to those reported with 5-fluorouracil alone, these results failed to demonstrate an increase in response rate in the treatment of advanced colorectal cancer with the combination of 5-fluorouracil and folinic acid.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

M Natali, and M D'Aprile, and G Tonini, and M Leggio, and P Vici, and S Carpano, and F Angelini, and A Carassai, and M Lopez
January 1988, Cancer investigation,
M Natali, and M D'Aprile, and G Tonini, and M Leggio, and P Vici, and S Carpano, and F Angelini, and A Carassai, and M Lopez
October 1991, Tumori,
M Natali, and M D'Aprile, and G Tonini, and M Leggio, and P Vici, and S Carpano, and F Angelini, and A Carassai, and M Lopez
January 1990, European journal of cancer (Oxford, England : 1990),
M Natali, and M D'Aprile, and G Tonini, and M Leggio, and P Vici, and S Carpano, and F Angelini, and A Carassai, and M Lopez
January 1987, NCI monographs : a publication of the National Cancer Institute,
M Natali, and M D'Aprile, and G Tonini, and M Leggio, and P Vici, and S Carpano, and F Angelini, and A Carassai, and M Lopez
May 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Natali, and M D'Aprile, and G Tonini, and M Leggio, and P Vici, and S Carpano, and F Angelini, and A Carassai, and M Lopez
January 1995, Oncology,
M Natali, and M D'Aprile, and G Tonini, and M Leggio, and P Vici, and S Carpano, and F Angelini, and A Carassai, and M Lopez
October 1988, American journal of clinical oncology,
M Natali, and M D'Aprile, and G Tonini, and M Leggio, and P Vici, and S Carpano, and F Angelini, and A Carassai, and M Lopez
September 1988, European journal of cancer & clinical oncology,
M Natali, and M D'Aprile, and G Tonini, and M Leggio, and P Vici, and S Carpano, and F Angelini, and A Carassai, and M Lopez
November 1995, European journal of cancer (Oxford, England : 1990),
M Natali, and M D'Aprile, and G Tonini, and M Leggio, and P Vici, and S Carpano, and F Angelini, and A Carassai, and M Lopez
June 1998, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!